The GEMINI-Gastric study, a phase II, open-label, multi-drug, multi-center study, is looking to evaluate the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of multiple novel immuno-oncology (IO) agents plus chemotherapy combinations in patients with previously untreated HER2-negative advanced or metastatic GC/GEJC [67]. Here, ERBB2 is linked to gastric cancer.